Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorigerlimab with Docetaxel in mCRPC
NCT05848011Phase 2Completed
- Sponsor
- MacroGenics
- Start
- Sep 2023
- Primary completion
- Feb 2026
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Lorigerlimab + Docetaxel and Prednisone with Standard of care docetaxel and prednisone (2 arms). Primary endpoint: Radiographic Progression Free Survival. Started Sep 2023; status: completed.
02
Drugs
lorigerlimab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05848011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05848011.